March 4, 2019
Pfizer Japan launched its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Vizimpro (dacomitinib) on March 1 for the treatment of EGFR-mutated inoperable or recurrent non-small cell lung cancer (NSCLC). Vizimpro was approved in Japan in January and joined the...read more